Recent News & Research

*December 2022* Jill Feldman, EGFR Resisters Co-Founder As someone who has been fighting lung cancer indirectly and directly for almost 40 years, I have witnessed and celebrated the rapidly changing landscape of lung cancer diagnosis and treatment. After losing 2 grandparents and my dad to lung cancer when I was…

*November 2022* Osimertinib (Tagrisso) remains the preferred first-line therapy for patients with EGFR-mutated non–small cell lung cancer (NSCLC), Zosia Piotrowska, MD, MHS, told her audience at the 17th Annual New York Lung Cancers Symposium®.1 However, for those with classic EGFR mutations, exon 19 deletions and L858R substitutions, she believes the…

*October 2022* There was a focus on treating EGFR-positive NSCLC that has progressed after being treated with currently approved EGFR targeted therapies, with several presentations of new drug combinations and new EGFR targeted therapies. Data from the CHRYSALIS-2 trial was presented looking at giving a combination of the new EGFR…

*October 2022* During a Targeted Oncology case-based roundtable discussion, Zofia Piotrowska, MD, MHS, discussed the data from clinical trials supporting mobocertinib and amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion mutation. Read more.

*October 2022* RESULTS: As of January 2020, 42 patients were enrolled (N = 36 efficacy-evaluable). Neuropathies were the most common any-grade adverse events reported, with 24 of 42 patients (57%) experiencing at least one event. The pharmacokinetic profile of Teliso-V plus erlotinib was similar to Teliso-V monotherapy. Median PFS for all…

*October 2022* Targeted treatment options for patients with HER2-mutant non–small cell lung cancer (NSCLC) have been slow to reach benchmarks for approval given the limited patient populations harboring this disease characteristic. Three classes of agents have demonstrated efficacy in patients with HER2-mutant disease: tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and…

*October 2022* Drs Benjamin Levy, Neil Morganstein, and Bhuvana Ramkumar discuss challenges of procuring for molecular testing in patients with NSCLC. Watch video here.

*October 2022* Dr. Neil Love and Dr. Pasi Janne discuss the current and future management of EGFR+ NSCLC.  Listen to the audio or read the transcription.